Aura Biosciences, Inc. (NASDAQ:AURA) Receives $22.75 Average Price Target from Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has earned a consensus recommendation of "Buy" from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $22.75.

AURA has been the topic of a number of analyst reports. JMP Securities set a $19.00 target price on shares of Aura Biosciences in a research report on Wednesday, March 26th. Citigroup restated an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th. HC Wainwright set a $25.00 price objective on Aura Biosciences in a research note on Tuesday, March 25th. Finally, Lifesci Capital upgraded Aura Biosciences to a "strong-buy" rating in a report on Friday, January 31st.

Aura Biosciences Trading Down 2.0 %

Shares of Aura Biosciences stock traded down $0.11 on Friday, hitting $5.46. 15,310 shares of the company traded hands, compared to its average volume of 199,617. Aura Biosciences has a 12-month low of $3.40 and a 12-month high of $12.38. The firm's 50-day simple moving average is $6.85 and its 200 day simple moving average is $8.23. The company has a market cap of $274.23 million, a P/E ratio of -3.16 and a beta of 0.43.

Remove Ads

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.09). Analysts predict that Aura Biosciences will post -1.66 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now directly owns 304,692 shares of the company's stock, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 23,045 shares of company stock worth $177,242. Insiders own 5.40% of the company's stock.

Institutional Investors Weigh In On Aura Biosciences

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new position in Aura Biosciences during the 4th quarter worth $50,000. GAMMA Investing LLC grew its holdings in shares of Aura Biosciences by 5,766.9% during the first quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock valued at $57,000 after buying an additional 9,573 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Aura Biosciences in the 4th quarter valued at $87,000. ProShare Advisors LLC acquired a new stake in Aura Biosciences during the 4th quarter worth about $127,000. Finally, Harvest Investment Services LLC purchased a new stake in Aura Biosciences during the 4th quarter valued at about $133,000. Institutional investors own 96.75% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.